Galaxy Securities: The 5G+ industrial chain will be developed in a large scale, and the sub-sector prosperity margin will be optimized to improve the quality target. china galaxy Securities said that the demand for communication equipment as the base of the computing infrastructure of the digital economy is expected to usher in high growth, and related sectors may usher in greater opportunities, focusing on the empowerment of related industrial chains by emerging industries such as operators, optical communications, quantum communications and 5G applications. It is suggested to pay attention to: network infrastructure upgrade+telecom operators, optical module leaders, quantum communication leaders, Internet of Things and cutting-edge applications led by central enterprises.The negotiation between Myriad and United Health Insurance may be extended to the beginning of 2025, and the negotiation between Myriad Genetics and UnitedHealthcare on the genetic test of Myriad may continue until the beginning of 2025. Myriad reiterated its estimate of the financial impact of the United Health Insurance Company's updated medical policy in 2024.The restricted shares with a market value of 463 million yuan were lifted today. Smith Barney, Foreign Service Holdings and Aimeike were among the top companies in terms of market value. On Wednesday (December 11th), the restricted shares of four companies were lifted, with a total lifting amount of 31.3389 million shares. According to the latest closing price, the total lifting market value was 463 million yuan. Judging from the amount of lifting the ban, one company lifted more than 10 million shares. Smith Barney Technology, Foreign Service Holdings and Pulitzer were among the top, with 24,446,500 shares, 6,503,200 shares and 234,800 shares respectively. Judging from the market value of lifting the ban, the number of shares lifted by a company exceeds 100 million yuan. Smith Barney Technology, Foreign Service Holdings and Aimeike are among the top companies in terms of market value, with market values of 392 million yuan, 34.8574 million yuan and 33.43 million yuan respectively. Judging from the proportion of shares released from the ban to the total share capital, the proportion of one company released from the ban exceeded 10%. Smith Barney Technology, Foreign Service Holdings and Aimeike are among the top companies, with the lifting rates of 29.38%, 0.28% and 0.05% respectively.
Russia said it had fought against the Ukrainian ammunition depot and repulsed Russia's repeated attacks. On the 10th local time, the Russian Defense Ministry reported that the Russian army had taken control of a settlement in Donetsk on the same day, and attacked the Ukrainian ammunition depot, electronic warfare base stations, armored vehicles and other targets. Russian air defense forces shot down several rockets and dozens of drones of the Ukrainian army. In addition, the Russian army continued to crack down on Ukrainian personnel and equipment in Kursk region, Russia. On the same day, the General Staff of the Ukrainian Armed Forces issued a war report, saying that as of the afternoon of the 10th, the Ukrainian army had nearly 100 battles with the Russian army in Kharkov, Kupyansk, Hongliman and other areas. The Ukrainian army continued to hold its ground and repelled many Russian attacks.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.A new generation of quantum chips has achieved a breakthrough in error correction capability. According to a paper published in Nature magazine on the 10th, Google's latest generation of quantum chips has achieved a breakthrough in error correction capability, that is, the error is suppressed below a critical threshold. This quantum error correction function is considered as a necessary condition to realize the practical application of quantum computing in the future. After the performance of the chip is expanded, it may be able to promote the operation requirements of large-scale fault-tolerant quantum computing.
Nippon Steel's share price rose by 1.2% shortly after the opening on Wednesday, and it is basically flat at present. In the news, US President Biden plans to formally prevent Nippon Steel from acquiring American steel companies for $14.1 billion. American steel stocks plunged overnight, once falling by 22%, and finally closed down by 9.7%.Policy combination boosts confidence, and public offering: China's assets will usher in a further increase in valuation. On December 9, the Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting to analyze and study the economic work in 2025. A number of public offerings said that the meeting sent a very positive signal. At present, the economy is resilient, the investor structure is constantly optimized, and the market activity continues to increase. China assets may have an opportunity to raise their valuations again. From the perspective of funds, Jing Shun Great Wall Fund analyzed that the current A-share market is in the most active stage since 2015, and there are many potential bulls in the market. Policy expectations are expected to drive incremental funds into the market, forming a resonance between emotions and funds. (SSE)CITIC Securities: The logic of "grabbing exports" is expected to support the short-term performance of China's exports. According to the CITIC Securities Research Report, in November, China's exports maintained a certain growth rate, exports to emerging markets maintained a high growth rate, and exports of mechanical and electrical products performed brilliantly. In the short term, both CCFI index and SCFI index are on the rise, and the logic of "grabbing exports" is expected to support the short-term performance of China's exports. In the long run, if the United States imposes tariffs on China, China's export performance may be dragged down. However, based on the analysis of the import share structure of the United States, the European Union, Vietnam, Mexico and other economies, we can see that the current pattern of China's trade diversification has improved compared with the last round of Sino-US trade friction, and the trade between emerging markets and China has become closer and closer. The imposition of tariffs by the United States on China may affect the bilateral trade between China and the United States more, and domestic enterprises going to sea and re-exporting trade may still be effective ways to hedge the impact of US tariffs on China.
Strategy guide 12-13
Strategy guide
12-13
Strategy guide 12-13